ghostwriting - getting closer to the test tube
Get flash to fully experience Pearltrees
Dentists leafing through The Journal of the American Dental Association last May found a study concluding that a new drug called Bextra offered relief from one of their patients' worst nightmares -- the acute pain that follows dental surgery. Federal regulators had rejected that conclusion only six months before, leaving Bextra's marketers, Pharmacia and Pfizer, hard pressed to sell it as an advance over Celebrex, their earlier entry in a crowded market for pain drugs. The new study helped light a fire under Bextra.
Madison Ave. Has Growing Role In the Business of Drug Research
D entists leafing through The Journal of the American Dental Association last May found a study concluding that a new drug called Bextra offered relief from one of their patients' worst nightmares - the acute pain that follows dental surgery. Federal regulators had rejected that conclusion only six months before, leaving Bextra's marketers, Pharmacia and Pfizer, hard pressed to sell it as an advance over Celebrex, their earlier entry in a crowded market for pain drugs. The new study helped light a fire under Bextra. Its sales soared 60 percent over the three months that followed, according to industry data.
Big Pharma and Madison Avenue
Omnicom Group Inc. is an American global advertising , marketing and corporate communications holding company , headquartered in New York City , USA. It is the world's top corporate media services conglomerate [ 1 ] and one of the "Big Four" agency companies (alongside WPP , Interpublic and Publicis ). [ 2 ] The company oversees an international network of more than 1,500 agencies and provides services for over 5,000 clients in more than 100 countries worldwide. [ 3 ] [ 4 ] As a strategic holding company, Omnicom manages a portfolio of global market leaders; Omnicom's agencies provide marketing and communications services in the disciplines of advertising, customer relationship management (CRM), strategic media planning and buying, digital and interactive marketing, direct and promotional marketing, public relations (PR) and other specialty communications.
Omnicom Group
Interpublic Group of Companies
The Interpublic Group of Companies, Inc. ( IPG ) ( NYSE : IPG ) is an American multinational advertising and public relations company. It is one of the "big four" global advertising agency (the others being Omnicom , WPP and Publicis ). Headquartered in New York City , it has 41,000 employees and reported full−year revenues of US$6.5 billion for 2010. Its subsidiaries specialize in consumer advertising, interactive marketing, media planning and buying, public relations and other specialized disciplines like sports and event marketing. The company’s current chairman and CEO is Michael I. Roth.WPP plc is a British multinational advertising and public relations company with its main management office in London , United Kingdom , and its executive office in Dublin , Ireland . [ 3 ] It is the world's largest advertising company by revenues, and employs around 162,000 people in 3,000 offices across 110 countries. [ 2 ] [ 4 ] It owns a number of advertising, public relations and market research networks, including Grey , Burson-Marsteller , Hill & Knowlton , JWT , Ogilvy Group , TNS , Young & Rubicam and Cohn & Wolfe . [ 2 ] WPP has a primary listing on the London Stock Exchange and is a constituent of the FTSE 100 Index . It has a secondary listing on NASDAQ . [ edit ] History
WPP plc
Publicis
Publicis Groupe is a French multinational advertising and public relations company, headquartered in Paris, France. It is one of the world's three largest advertising holding companies (the others being Omnicom , and WPP ). Its current president is Maurice Lévy . Publicis Groupe S.A. provides digital and traditional advertising, media services, and specialized agencies and marketing services (SAMS) to national and multinational clients. [ edit ] Overview
Bart Penders Annemiek Nelis Laboratory ethnographies have provided valuable insights in the workings of contemporary science and technology and about facts in the making.
The Social Study of Corporate Science: A Research Manifesto
John Verbakel, Vice President Research and Development | Unilever
In 2008 kondigde Unilever plannen aan om haar Research & Development-activiteiten opnieuw te organiseren. De drie wereldwijde R&D-organisaties (Foods R&D, HPC R&D en Corporate Research) worden samengevoegd tot één Unilever R&D-organisatie onder leiding van Chief R&D Officer Geneviève Berger. Unilever heeft wereldwijd zes strategische onderzoekslocaties geselecteerd. Eén daarvan is Unilever Research & Development Vlaardingen (URDV). Hier wordt Unilevers wereldwijde R&D op het gebied van was en voedingsmiddelen geconcentreerd. Expertisecentrum
Prof Accuses Colleagues of Slanted Research
By Paul Basken A University of Pennsylvania psychiatry professor has accused his department chairman and four colleagues of publishing an article that was ghostwritten on behalf of a pharmaceutical company and made unsupported claims for one of its best-selling drugs. The medical-journal article, published in 2001, "was biased in its conclusions" and "made unsubstantiated efficacy claims and downplayed" negative side effects of the antidepressant drug Paxil, according to a complaint filed by lawyers for Jay D. Amsterdam, a professor of psychiatry at Penn. Dr.
Amsterdam, J.D., Newberg, A : Dopamine Transporter Density in Bipolar Type II and Unipolar Major Depressive Episode . Neuropsychobiology 55: 167-170, 2007. Michelson D, Adler L, Amsterdam JD, Dunner D, Nierenberg A, Reimherr F, Schatzberg Am Kelsey D, Williams D : Addition of atomoxetine for depression incompletely responsive to sertraline: A randomized, double blind, placebo controlled study. Journal of Clinical Psychiatry 68: 582-587, 2007. Newberg AB, Amsterdam JD, Shults J : Dopamine transporter density may be associated with the depressed affect in healthy subjects. Nuclear Medicine Communications 28(1): 3-6, 2007.
Jay. D. Amsterdam
By Paul Basken Universities have been struggling for years with the problem of researchers who let industry-financed ghostwriters draft biased summaries of their work for publication in medical journals. They're now getting some blunt advice on how to stop it, including from perhaps the most qualified experts: the ghostwriters themselves. In a pair of articles published Tuesday by PLoS Medicine , two professional medical writers outlined changes that both universities and the journals could make.
Universities Get Advice on How to Avoid Ghostwriting Scandals in Research Articles - Government
Citation: Logdberg L (2011) Being the Ghost in the Machine: A Medical Ghostwriter's Personal View. PLoS Med 8(8): e1001071. doi:10.1371/journal.pmed.1001071 Published: August 9, 2011 Copyright: © 2011 Linda Logdberg.
Being the Ghost in the Machine: A Medical Ghostwriter's Personal View
If you are a certified professor and want to make a rebuttal or add a photo to your profile, please click here to log in. If you are a certified professor and you are already logged in you can Add Rebuttal , Add/Edit Photo or Edit Account Settings . If you have an account on RateMyProfessors.com but have not yet become a certified professor, please click here to register as a certified professor. With a certified professor account you can post blog-like responses to your ratings, as well as add a photo to your professor page. Your rebuttals will accessible from a tab to the right of the "User Comments and Ratings" tab. If you don't have an account at all, please click here to get started.
Linda Logdberg - Georgia Perimeter College [all campuses]
Aug. 9, 2011 — Rather than ensure the proper attribution of authorship, rules set up by leading medical journals to define and credit authorship of published articles are exploited by the pharmaceutical industry in its attempt to conceal and misrepresent industry contributions to the literature. This is a perspective contained in an article by Alastair Matheson, a medical writer based in the UK and Canada, who argues in this week's PLoS Medicine that the current International Committee of Medical Journal Editors (ICMJE) authorship guidelines allow for industry to exaggerate the contribution of named academic authors and downplay that of commercial writers who are excluded from authorship but listed as contributors in the small print. Matheson contends that the ICMJE guidelines should be fundamentally revised and the concept of origination given comparable importance to authorship and contributorship.